HCM (HUTCHMED Ltd) Bathi resik saben saham (EPS TTM)

HUTCHMED (China) Limited combines robust drug distribution in the PRC with the development of cutting-edge precision oncology therapies and targeted inhibitors. The TTM net income per share distribution reflects revenue dynamics, where 0.10 captures the current state of the parameter. Despite sales growth, the high cost of R&D projects is temporarily hindering the company's transition to stable operating profitability.
Rincian analitis lan laporan data perusahaan HUTCHMED Ltd (HCM)

EPS TTM measures the final profit per ordinary share over a trailing twelve-month period, allowing for an assessment of real capital efficiency without the impact of quarterly fluctuations. By analyzing the annual EPS TTM snapshot, an investor can see how the diversification of HUTCHMED (HCM) production chains across the US and Asia protects margins from regulatory risks, confirming the long-term financial stability of the biotech holding.